剛性連接子通過引入環(huán)（脂肪環(huán)、脂肪雜環(huán)、芳香環(huán)等）來替代線性連接子，可以有效減少藥物分子中可旋轉(zhuǎn)鍵數(shù)量，限制化合物構(gòu)象，從而有利于提高藥物分子對靶點的結(jié)合穩(wěn)定性；另一方面，剛性環(huán)相比線性分子更容易調(diào)節(jié)藥物分子的物理化學(xué)性質(zhì)，改善其DMPK，目前在蛋白降解劑類藥物中得到廣泛應(yīng)用。
Ethyl [1,4'-bipiperidine]-4-carboxylate dihydrochloride
Ethyl 3-(4-formylphenyl)propanoate
2-(4-Chlorophenyl)ethanol
tert-Butyl 4-(2-oxoethyl)piperidine-1-carboxylate
tert-Butyl (3-formylbicyclo[1.1.1]pentan-1-yl)carbamate
2-(3-((tert-Butoxycarbonyl)amino)cyclobutyl)acetic acid
tert-Butyl 4-(hydroxymethyl)benzylcarbamate
1,4-Cyclohexanedimethanol
Methyl 1-(5-bromopyrimidin-2-yl)piperidine-4-carboxylate
tert-Butyl 4-(4-aminophenyl)piperazine-1-carboxylate hydrochloride
(4-(3-Bromopropoxy)phenyl)boronic acid
2-(4-(3-Bromopropoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
tert-Butyl 3-(2-hydroxyethyl)azetidine-1-carboxylate
tert-Butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate hydrochloride
Ethyl 3-(4-bromophenyl)propanoate
4-(2-Bromoethyl)benzonitrile
2-(4-Boronophenyl)acetic acid
tert-Butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate
tert-Butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate
tert-Butyl 4-(azetidin-3-yl)piperazine-1-carboxylate
tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)piperazine-1-carboxylate
Methyl 4-(aminomethyl)bicyclo[2.2.2]octane-1-carboxylate
tert-Butyl (trans-4-(2-hydroxyethyl)cyclohexyl)carbamate
Ethyl 2-(trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)acetate
4-Ethynylphenylacetonitrile
2-(4-(((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)methyl)phenyl)acetic acid
2-(cis-4-((tert-Butoxycarbonyl)amino)cyclohexyl)acetic acid
4-(2-((tert-Butoxycarbonyl)amino)ethyl)benzoic acid
tert-Butyl 2-cyano-7-azaspiro[3.5]nonane-7-carboxylate
tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine-1-carboxylate
